Balaji Amines Limited will host a virtual group meeting with analysts and investors on Friday, August 21, 2026. The event is scheduled to begin at 4:00 pm IST and will be hosted by Phillip Capital (India) Private Limited.

The interaction is being conducted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company emphasized that the discussions during the session will be based solely on publicly available information.

Meeting Details

The company noted that no unpublished price-sensitive information (UPSI) relating to Balaji Amines will be disclosed during the interactions. The investor conference meeting remains subject to changes due to exigencies on the part of the investors or the company.

Abhijeet Kothadiya, Company Secretary and Compliance Officer, signed the intimation letter addressed to the BSE Limited and the National Stock Exchange of India Limited on August 13, 2026. The details are also available on the company’s website.

Balaji Amines reported a consolidated net profit of ₹78 crore for Q1FY27, a 110.19% increase from ₹37 crore in Q1FY26, driven by significant EBITDA margin expansion to 26%. The company’s total revenue rose 25.73% to ₹461 crore from ₹367 crore in the prior year period, demonstrating strong pricing power and operational efficiency despite declining sales volumes. The Board of Directors approved the unaudited financial results on July 27, 2026, and the investor presentation was filed with stock exchanges on July 29, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance

Consolidated revenue from operations increased to ₹456 crore from ₹358 crore in Q1FY26. Consolidated EBITDA rose sharply to ₹121 crore from ₹63 crore, representing a 91.51% year-on-year growth. The EBITDA margin expanded by 900 basis points to 26% from 17% in Q1FY26. Profit before tax grew 118.14% to ₹106 crore. Diluted earnings per share (EPS) increased to ₹23.13 from ₹11.73.

Standalone net profit rose to ₹72 crore from ₹40 crore in Q1FY26. Standalone revenue was ₹429 crore, up from ₹327 crore. Standalone EBITDA margin expanded to 26% from 20%. Cash PAT, defined as PAT plus depreciation and deferred tax, stood at ₹97 crore, up from ₹51 crore.

Volume and Segment Analysis

Total sales volumes declined to 21,587 MT in Q1FY27 from 27,570 MT in Q1FY26, reflecting a strategic shift towards higher-margin products. Amines volumes were 6,248.57 MT, Amines Derivatives volumes were 8,205.11 MT, and Specialty Chemicals volumes contributed 7,132.92 MT. The disproportionate growth in profitability relative to revenue highlights effective product mix optimization.

What the Numbers Show

The divergence between declining volumes and surging profitability underscores a pivot towards high-value specialty chemicals. The 900 basis point expansion in EBITDA margins indicates successful mitigation of input cost pressures through pricing power and operational efficiencies. Core chemical business Return on Capital Employed (ROCE) remained robust at 13% for FY26, compared to 12% in FY25, demonstrating strong fundamentals despite heavy capital expenditure.

New Projects and Expansion

Balaji Amines commissioned its 100,000 TPA Dimethyl Ether (DME) plant, India’s first commercial-scale facility for this product, targeting LPG blending and aerosol propellant markets. The N-Methyl Morpholine (NMM) and Acetonitrile (ACN) capacity expansions are on track for commissioning by end-FY27. Capital work-in-progress totals ₹165.60 crore for these projects.

Subsidiary Balaji Speciality Chemicals Limited (BSCL), which holds Mega Project Status, is executing a phased expansion. Unit-I expansion for EDA-based products is expected in FY27. Greenfield Unit-II at MIDC Chincholi, producing Hydrogen Cyanide (HCN), Sodium Cyanide (NaCN), EDTA, and EDTA-2Na, is targeted for FY27 commissioning. BSCL’s capital work-in-progress stands at ₹401.06 crore. These projects aim to build indigenous capabilities in cyanide chemistry, reducing import reliance for pharmaceutical and agrochemical industries.